Pinoline may be used as a probe for CYP2D6 activity

Drug Metabolism and Disposition

Volumn 37, Issue 3, 2009, Pages 443-446

  Jiang, Xi Ling ^a   Shen, Hong Wu ^a   Yu, Ai Ming ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXYTRYPTOLINE; ALPHA NAPHTHOFLAVONE; BUFURALOL; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIETHYLDITHIOCARBAMIC ACID; ISOENZYME; KETOCONAZOLE; METHOXSALEN; O DEMETHYLASE; PINOLINE O DEMETHYLASE; QUINIDINE; RECOMBINANT ENZYME; SEROTONIN DERIVATIVE; SULFAPHENAZOLE; TICLOPIDINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; LIVER MICROSOME METABOLISM; MICHAELIS MENTEN KINETICS; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; CARBOLINES; CYTOCHROME P-450 CYP2D6; HUMANS; MICE; MICE, TRANSGENIC; MICROSOMES, LIVER; MOLECULAR PROBES;

MUS; MUS MUSCULUS;

EID: 61449111025     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.025056     Document Type: Article

References (22)

1. Airaksinen MM, Ho BT, An R, and Taylor D (1978) Major pharmacological effects of 6-methoxytetrahydro-beta-carboline, a drug elevating the tissue 5-hydroxytryptamine level. Arzneimittelforschung 28:42-46.
2. Cooper EJ, Hudson AL, Parker CA, and Morgan NG (2003) Effects of the beta-carbolines, harmane and pinoline, on insulin secretion from isolated human islets of Langerhans. Eur J Pharmacol 482:189-196.
3. Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR, and Gonzalez FJ (2001) The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 60:1260-1267.
4. Felmlee MA, Lon HK, Gonzalez FJ, and Yu AM (2008) Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 36:435-441.
5. Frank D, Jaehde U, and Fuhr U (2007) Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 63:321-333.
6. Gonzalez FJ and Yu AM (2006) Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol 46:41-64.
7. Herraiz T and Galisteo J (2004) Endogenous and dietary indoles: a class of antioxidants and radical scavengers in the ABTS assay. Free Radic Res 38:323-331.
8. Ho BT, Taylor D, Walker KE, and McIsaac W (1972) Metabolism of 6-methoxytetrahydro-carboline in rats. Xenobiotica 2:349-362.
9. Pahkla R, Harro J1 and Rägo L (1996) Behavioural effects of pinoline in the rat forced swimming, open field and elevated plus-maze tests. Pharmacol Res 34:73-78.
10. Piñol-Ripoll G, Fuentes-Broto L, Millán-Plano S, Reyes-Gonzáles M, Mauri JA, Martínez-Bailarín E, Reiter RJ, and García JJ (2006) Protective effect of melatonin and pinoline on nitric oxide-induced lipid and protein peroxidation in rat brain homogenates. Neurosci Lett 405: 89-93.
11. Qi W, Reiter RJ, Tan DX, Manchester LC, Siu AW, and Garcia JJ (2000) Increased levels of oxidatively damaged DNA induced by chromium(TH) and H202: protection by melatonin and related molecules. J Pineal Res 29:54-61.
12. Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M and Hiratsuka M (2008) Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2,10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos 36:2460-2467.
13. Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B, and Li C (2007) Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 35:1292-1300.
14. Tang GY, Ip AK, and Siu AW (2007) Pinoline and N-acetylserotonin reduce glutamate-induced lipid peroxidation in retinal homogenates. Neurosci Lett 412:191-194.
15. Yu A, Kneller BM, Rettie AE, and Haining RL (2002) Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 303:1291-1300.
16. Yu AM (2008) Indolealkylamines: biotransformations and potential drug-drug interactions. AAPS J 10:242-253.
17. Yu AM, Idle JR, and Gonzalez FJ (2004) Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 36:243-277.
18. Yu AM, Idle JR, Herraiz T, Kupfer A, and Gonzalez FJ (2003) Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307-319.
19. Yu AM, Qu J, Felmlee MA, Cao J, and Jiang XL (2009) Quantitation of human cytochrome P450 2D6 protein with immunoblot and mass spectrometry analysis. Drug Metab Dispos 37:170-177.
20. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, and Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573-585.
21. Zanger UM, Raimundo S, and Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23-37.
22. Zhang WY, Tu YB, Haining RL and Yu AM (2009) Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27 and CYP2D7 isozymes. Drug Metab Dispos 37:1-4.